INTRODUCTION
There have been several studies on the biochemical processes related to preeclampsia, intrauterine growth restriction, and premature rupture of membranes that provide evidence that oxidative stress may be part of the pathological processes in these diseases. Therefore antioxidants such as vitamin C may be preventive. (1) (2) (3) (4) The biochemical evidence prompted researchers to pursue further studies to investigate whether vitamin C use during pregnancy would change the incidence rate of certain obstetrical outcomes. Often preeclampsia and premature rupture of membranes are indications for preterm delivery and the nutritional status of a woman has also been implicated in premature birth.(5) Therefore, this review will attempt to answer the question: does vitamin C use during pregnancy decrease the incidence of preterm birth? (Preterm birth for the purpose of this review is birth before completion of the 37 th week of gestational age)
Burden of Suffering
Almost one third of all infant deaths in the United States (US) are associated with preterm birth. (6) Even if a premature infant survives the first year of life, they have higher death rates during childhood than children born at full term. (7) Not only is preterm birth a significant risk factor for infant mortality, it is also a significant cause of morbidity. It should be noted that most of the data available on morbidity can be confounded by the low birthweight typical of preterm infants. Low birthweight can be caused by other factors besides birth at an early gestational age such as intrauterine growth restriction. However, in most infants, their birthweight and gestational age at delivery are closely correlated. Evidence has demonstrated [3] higher incidence rates of blindness, deafness, cerebral palsy, lower IQ, and subnormal height in babies born with low birthweight and low gestational age.(8)
Epidemiology
According to the Centers for Disease Control and Prevention (CDC), in 2009 12.2% of all births in the US were pre-term. Although this represents a decrease from the previous two years where the rate was 12.7% in 2007 and 12.3% in 2008, the rate remains substantially higher than it was in 1990 when the rate was 9.7%. In general, the rate of preterm births has been increasing in the US since the 1980s with a peak occurring in 2006 at 12.8% of all births. (9) The causes behind this trend are multi-factorial. One explanation for the increase in preterm birth rate is the increased use of artificial reproductive technology (ART) and the associated increase in multiple gestation pregnancies. A multiple gestation pregnancy is an important risk factor for preterm birth because 50% of all twins and 90% of all triplets are born prematurely. Multiple gestations as a risk factor for preterm birth is independent of the use of ART. However, the increased use of ART is contributing to a rise in the incidence of multiple gestations. For example: the rate of twin births increased 70% between 1980 and 2004. (10) Preterm birth continues to have a large racial disparity within the US. In the 1990s the rate of preterm birth for African-Americans was twice that of Caucasian Americans. The gap has decreased somewhat but the decrease is more as a result of increasing rates in Caucasian
Americans rather than a decrease for African Americans. (11) The difference in incidence rates between African-Americans and Caucasians in the US has socioeconomic and genetic causes.
Specific gene loci continue to be identified that may contribute to preterm birth but also from a public health perspective the socioeconomic effect is worrisome. (12) Evidence has not shown that enhanced prenatal care reduces the incidence of preterm birth but it does support the benefit [4] of obtaining standard of care which is not as readily available for all socioeconomic groups. (13) The World Health Organization estimates an incidence rate 9.6% for preterm births worldwide and found increasing trends in preterm birth rate similar to the US in the United Kingdom and the Scandinavian countries.(14)
Risk Factors
The description of preterm birth risk factors has been difficult for three reasons: One, most cases of preterm birth occur in women with no identifiable risk factor. Secondly, many of the risk factors are also associated with other obstetrical complications which themselves are preterm birth risk factors. Lastly, there is not an animal model useful for studying the question.
A complete table of characteristics thought to be risk factors for preterm birth is included in
Appendix C and some of the better defined ones pertinent to this review will be discussed here.
As discussed above, multiple gestations and African-American race are both risk factors for preterm birth. Previous history of preterm birth and second trimester abortions are also important risk factors for preterm birth. One of the more recent large cohort studies involving >450,000 women showed after a women delivered between 32 and 36 weeks gestational age, the next delivery had an odds ratio of 6.12 to be preterm compared to women with a delivery after 37 weeks. Women with deliveries <32 weeks had even higher odds ratios of 12.0-13.1 to have a subsequent preterm birth.(15) Any type of miscarriage can increase the risk of subsequent preterm birth but second trimester abortions have the largest affect. Two retrospective cohort studies had preterm rates of 39% (16) and 33% (17) in the pregnancy following a second trimester abortion.
Preeclampsia can be an iatrogenic cause of preterm birth and is also independently a risk factor for future preterm births even if the later pregnancy is normotensive. Two large cohort [5] studies followed women for at least two pregnancies. Each showed increased risk of preterm birth in a pregnancy following one complicated by preeclampsia even when the second pregnancy was normotensive. The amount of increased risk was dependent on the gestational age at delivery and at diagnosis of preeclampsia during the first pregnancy. For all combinations, the rate of preterm birth was higher than for those in the cohort without preeclampsia in the first birth. (18, 19) The risk of a preterm birth in women with a history of preeclampsia is also increased if a future pregnancy is also complicated by preeclampsia.
Some other risk factors for preterm birth include chronic medical diseases and smoking.
In a Swedish cohort study involving 311,977 women, smoking was shown to be a risk factor for preterm birth in a dose dependent manner. The study showed increased rates of other obstetrical complications also associated with preterm birth (e.g. preeclampsia) but after controlling for these, an independent increase in risk was also found. (20) In a prospective observational study using 2,738 women in a control group, 462 women with diabetes mellitus, and 761 women with chronic hypertension. Both chronic diseases showed an increase risk for preterm birth. Women with diabetes had a preterm birth rate of 38%, those with hypertension-33.1%, and women in the control group-13.9%.(21)
Existing Interventions
The data on many suggested intervention for preventing preterm labor is limited.
Approximately 20% of preterm births in the US are secondary to iatrogenic interventions related to other obstetrical complications.(8) A discussion of the prevention and treatment methods for each of these is beyond the scope of this review. Some interventions directly related to decreasing risk factors mentioned above include smoking cessation and judicial ART use to reduce multiple gestations. Other fairly straight forward interventions targeted towards specific [6] risk factors include treatment of symptomatic bacteruria, avoidance of cocaine, cervical cercalge for patients with cervical incompetence, proper nutrition, avoidance of occupational stress, and avoiding a short interpregnancy interval.
Two interventions that are more widely targeted at preventing preterm birth are supplemental progesterone and tocolytic therapy. A systematic review of 8 RCTs and nine other articles found evidence for the use of progesterone to decrease the risk of preterm birth. The strongest evidence was found in women with a prior history of preterm birth; however there was also evidence of a reduction in risk for women with a shortened cervix. (22) Tocolytic therapies are interventions aimed at stopping the labor process. Therefore, any woman experiencing preterm labor may be given these therapies with the goal of delaying delivery. In general, no therapy has been found to significantly delay the labor process and most tocolytic therapies are used primarily to allow the administration of steroids for 48hrs to enhance infant lung maturity prior to delivery. There are many possible interventions that fall under tocolytic therapy including: beta-agonists, magnesium sulphate, oxytocin receptor antagonists, cox inhibitors, calcium channel blockers, and nitric oxide donors. Unfortunately, the studies investigating each of these therapies are of varying quality and a full discussion of each is beyond the scope of this review. The key point to be made about tocolytic therapy is that it is not preventive; rather it is an intervention during preterm labor to attempt to delay the labor for days at most.(23)
Vitamin C for Prevention
According to the Institute of Medicine, a pregnant woman 19 years or older has a recommended dietary allowance for vitamin C of 85mg/day and for those 18 years or younger the recommendation is 80mg/day. Vitamin C or ascorbic acid is water soluble nutrient with antioxidant properties and is a cofactor in the synthesis of camitine, collagen, and [7] neurotransmitters. (24) The antioxidant properties of vitamin C may have significant value during pregnancy given the link between oxidative stress and unfavorable outcomes such as preeclampsia and intrauterine growth restriction.(1)(2) Vitamin C is also involved in the metabolism of iron in the body and therefore may exert an additional beneficial affect during pregnancy by preventing anemia. (24) Historically, vitamin C has not been taken during pregnancy as a stand-alone nutritional supplement; however, it is contained in many multivitamin formulations which are often utilized. The increased recommended daily intake is based on higher metabolic demands during pregnancy and not for treatment or prevention of any specific pathologic process.
In the US, around 50% of preterm births are due to preterm labor, 30% secondary to premature rupture of membranes, and 20% secondary to another condition (such as associated with preeclampsia). (8) Relevant to preterm births due to preterm labor, a review of available studies found maternal nutritional status can affect gestational length. There was an increase in the incidence rate of preterm birth in women with nutritional deficiencies. Myatt and Cui(1) also described histological and biochemical evidence that using vitamin C for its antioxidant properties may be helpful in pregnancies with intrauterine growth retardation and preeclampsia. Similar data has been provided by other studies in the past as well.(2, 4) Based on this growing body of evidence regarding the potential benefits of antioxidants many trials were begun to investigate the benefits and harms of using vitamin C at higher doses than what is typically present in a multivitamin supplement.
[8]
Harms of Vitamin C Use
The most common side effect from increased vitamin C ingestion is diarrhea and other gastrointestinal disturbances which are usually associated with intakes >3grams per day. (24) There is a case report of a fatal cardiac arrhythmia in a patient with iron overload and taking high doses of vitamin C. The case report argued there was increased oxidative stress leading to cardiomyopathy which caused the arrhythmia. (25) Another case report is available describing a woman having false-negative stool guaiac testing. The link between the ascorbic acid and falsenegative test was backed up with in vitro evidence. In the study, the patient was ingesting 1-2g of vitamin C/day and was using a guaiac test that may no longer be in use as the report is from
(26)

Key Question Formulation
The key question for this review was developed to determine if vitamin C use during pregnancy can reduce the number of preterm births regardless of whether the decreased incidence is an indirect effect by decreasing other obstetrical outcomes such as preeclampsia or premature birth or as a direct effect through any identified or unidentified mechanism. Details on the inclusion and exclusion criteria for studies included in this review are discussed in the methods sections below. After performing the database searches, I realized only studies on vitamin C alone and on vitamin C and E were found. Also, the studies could be easily divided into high and low risk study populations. Therefore the key question was answered for each grouping of intervention (C alone versus C and E) and risk profile (high versus low). A high risk population contained at least one of the important risk factors mentioned above: history of preterm birth, preeclampsia, or chronic maternal medical disease. The final key question for this review was:
• What is the evidence in randomized controlled trials performed at any time prior to this review for pregnant women in the US to use vitamin C prior to starting the third trimester as prevention of preterm birth when compared to placebo in populations similar to the US?
[10]
METHODS
Inclusion and Exclusion Criteria
Studies in this review were assessed using the following criteria to determine whether they should be included or excluded. The first criterion to determine the inclusion of a study pertains to the population of the study. To be included, a study needed to use a study population consisting of pregnant women. There were no limits on age, socioeconomic status, ethnicity/race, or any of factors to allow for the inclusion of all evidence available. If the population differed greatly from the US population on any of these factors, it was accounted for as part of the external validity evaluation.
The target of this review is to assess the effectiveness of vitamin C and therefore studies were only included if they used vitamin C in their intervention. More specifically, the studies should have utilized a vitamin C intervention starting prior to the third trimester. I decided studies should initiate the intervention prior to the third trimester to be more representative of a preventive therapy prior to many obstetrical outcomes being identified. On the other hand, it was not required for studies to start early than the second trimester because it would be difficult to enroll patients this early in their pregnancy and most abortions occurs in the first trimester.
Also, no limit was placed on the vitamin C dose level as part of my inclusion/exclusion criteria.
Similar to above, this was done to allow the inclusion of all available evidence during the study assessment step of this review. During the internal validity, an assessment regarding the dose level of vitamin C used is made. Study's that do not provide evidence that their dose would have a meaningful impact based on their population's dietary patterns or used high enough doses that this evidence was unnecessary would be graded poor and excluded from the conclusions of this [11] review. Studies were included if the intervention included vitamin C and up to one other supplement other than iron. This was done to allow for co-administration of other antioxidant therapies while limiting the confounding effect of other therapies by not allowing for multi-drug regimens.
Every study included in this review needed to have a control group taking a placebo.
Requiring the studies to use a control group helps eliminate the placebo effect and enhances blinding. Part of the placebo effect is a change in patient's expectations when taking medication.
This change in expectation can affect outcomes by changing physician-patient interactions. For example, all participants are aware of the intervention due to the consent process and without a placebo, the control group would know they are not getting the intervention. Therefore, participants in the control group may have a lower threshold for visiting the physician because they perceive they are 'missing out' on the treatment. The second benefit of having a placebo controlled trial deals with blinding. If participants are not receiving a placebo they are likely to know they are part of the control group and the clinician may become aware of this as well. The patient or clinician's knowledge as to whether they are part of the intervention or control arm may subconsciously affect the treatment plan utilized. Therefore, all trials included in this review needed to be double-blinded to enhance internal validity. The use of a placebo in the control arm enhances the blinding within the trial.
Each study included in this review must provide data on the number of pre-term births, defined as births occurring prior to 37 weeks as one of their reported outcomes. Studies published at any time were included in the review to ensure as much of the available evidence was included. Studies were included only if performed in Organization for Economic Cooperation and Development (OECD) member countries. This limitation was used to increase the [12] generalizability of the study results to the US population. As mentioned above, if significant differences in the baseline characteristics of the study population and the US population were reported within the study, this was taken into account as part of the external validity assessment.
The final criterion used to define the inclusion and exclusion criteria for this review is the study design which needed to be a randomized control trial. The above set of criteria is listed below in PICOTS format in Table 1 . 
Data Sources and Searches
I searched PUBMED, Cochrane library, and EMBASE using the terms ("Vitamin C" OR "Ascorbic Acid") AND (Pregnancy OR Pregnant). A research librarian was consulted to help in developing these terms and any limitations used during the searches. For details on the search strategy please see Appendix A. I also searched clinicaltrials.gov for any unpublished and ongoing studies relevant to this review. I also hand searched the reference sections of the articles found in the above searches for any further studies relevant to this review. These searches were all limited to English language and human subjects and performed with no date limits giving results since the inception of the relevant database.
[13]
Study Selection
Another reviewer and I analyzed the results of the above searches looking at the titles and abstracts to identify randomized controlled trials related to this review. Only studies that could be easily excluded were eliminated at this point with the rest being retained for full text review to determine if they met the inclusion criteria for this review. During the title and abstract phase of eliminating articles, if either reviewer felt the article should be included for full text review, it was. If there was any disagreement after independent full text review, the other reviewer and I met to discuss the article and any concerns about its inclusion or exclusion. If a consensus could not be reached after this meeting, a third reviewer was utilized. At this point all studies to be included in this review were identified and quality grading began. If a study had multiple articles published based on its results, the study was given a single quality score and all data pertinent to this review was utilized.
Study Quality Assessment -Internal Validity
Another reviewer and I assessed the quality of each study included in the review. We used the USPSTF internal validity criteria for randomized controlled trials as the guidelines to assess the quality of each individual study. This resulted in grades of good, fair, or poor for each study. While grading each study's internal validity the first consideration pertains to how effectively the studies setup the initial intervention and control groups. Studies are graded based on how well they established concealment, maintained randomization, and if the groups contained equivalent distributions of possible factors that could be confounding. Ideally each study would maintain double-blinding and none of the confounders would have statistically significant differences between each group. Once the groups have been established the next way a study can enhance internal validity is dependent on how well the groups are maintained which [14] is determined by attrition, crossovers, adherence, and contamination. In order to properly evaluate a study, it should report information on these rates. However, if some of the information is not available in the published study, it will still be graded based on what is available with conservative assumptions about the missing data. (27) As described above, the creation and maintenance of the intervention and control groups are important factors in determining the internal validity of a study. However, other factors also contribute. One other factor is whether the study utilized measurements appropriate for the study, equal between groups, valid, and precise. For this review the outcome is a birth prior to 37 weeks gestational age. Therefore, each study should measure gestational age using the same methods between groups and report what methods were used (e.g. last menstrual period or ultrasound dating). Some other important considerations for study's being reviewed here are that the intervention is clearly defined and meets the inclusion criteria and the data is reported as intention to treat. Another aspect of each study we used to determine internal validity was whether the study provided any information on the baseline intake level of the vitamin(s) included in their intervention. Ideally, a study would gather information on dietary patterns and report the expected intake for study participants based on their normal diet. The internal validity of the study would be enhanced if the dose of the intervention was higher than the baseline dietary intake of the participants. This interplay between the baseline dietary intake of the study population and intervention dose is also addressed as part of the external validity due to differences in dietary patterns in the US population and some of the study's source population. (27) For all of the above aspects of our quality assessment the totality of their effect on internal validity was determined independently by each reviewer to determine a grade of good,
[15] fair or poor. Any discrepancies between reviewers were handled by meeting to attempt to reach a consensus or if necessary a third reviewer was utilized. Studies with poor quality are those considered to have a 'fatal flaw' in their design and were excluded from the data synthesis and conclusions portion of this review. Studies rated as fair, did not meet the highest standards but still provide useful information for this review and are used in the data synthesis and conclusion sections with the appropriate level of caution. (27) 
Study Quality Assessment -External Validity
Both reviewers assessed each study to determine its external validity. We used the USPSTF guidelines for external validity. In summary, studies are rated good if they have a high probability (>90%) that the outcome observed in the study would also occur in US primary care
given the same intervention. For a fair quality rating it would need to have a moderate probability (50-89%) and poor would be for anything less (<50%). Similar to the internal validity assessment, poor quality studies were those considered to have a 'fatal flaw' and were excluded from the data synthesis and conclusion sections. Good and fair quality studies were included in these sections with the appropriate caution when utilizing the studies rated as fair. (27) Assessing the external validity of a study included in this review can be broken down into three broad categories: the study population, the situation of the study, and the providers in the study. While assessing the studies for external validity in relation to the study population we tried to determine if the study population represented the patient population in the US well. One key characteristic, if reported by the study, would be to assess differences in nutritional status prior to study initiation. Also, we can assess the demographic information of the study participants relative to the US population. Another important aspect is whether the study's [16] population presented with more or less risk factors than a comparable group in the US. The results of this review were divided between studies with high and low risk study populations based on their inclusion and exclusion criteria. For this review, the number of possible risk factors is high and therefore smaller studies may have some variability on individual comorbidities. Therefore, a goal of our assessment was to attempt to quantify whether it was a systematic problem with the study's population related to recruitment/study design or if it was merely an expected result due to random occurrences in a small study population. (27) Another study design characteristic relevant to the study population is the recruitment method used. Therefore we assessed this in our external validity grading. Some of the data we looked at included: rate of refusal by those approached about the study, source population for recruitment, and intensity of recruitment tactics. These factors may affect the adherence to treatment of the study population. When analyzing a study's protocol regarding adherence, we were looking for any measures that might increase the adherence to the intervention to a level that is not representative of the general patient population for this review. (27) The other two broad categories assessed while grading studies for their external validity were the situation within which the study was performed and the providers included in the study.
The situation of the study pertains to the healthcare system, country, study locations, and cost of the intervention and whether these factors are similar to what might be expected when introducing the intervention to the all pregnant women. The external validity of a study may be decreased if the providers in the study have a skill set or knowledge set that differs from the practitioner expected to be providing the intervention to the regular patient population. For the intervention under review here, this should not be an issue for many studies. However, pertinent [17] to the outcome, some providers may be more or less capable in their attempts to delay delivery if necessary and this will be considered during the assessment. (27) 
Data Collection
Both reviewers abstracted data from each study to be used in the quality assessments mentioned above and also for use in analyzing the outcomes results of the studies in developing the conclusions of this review. The data was placed in an Excel file for reference. Below is an example list of the type of data compiled for each study:
• Study Population-Demographic Data, Size, Dropout Rates 
Data Synthesis
Using the quality rating given to each individual study, a qualitative comparison was performed for the outcome measure: pre-term birth. The data will be reported for studies deemed to have overall quality of fair or good. Results will also be divided into groups of studies based on the risk level of the study population and intervention used. No computational combination of results will be derived for this review. However, a discussion of the synthesis of evidence from the studies identified will be included. For this review's discussion, studies considered to be of good quality will be given more influence upon the final conclusion than [18] those with fair quality ratings. For this review, as above, we will be utilizing methods similar to USPSTF when analyzing preventive services. Evidence for the key question, based on intervention and risk grouped, will be graded as convincing, adequate, or inadequate. The USPSTF uses the following six questions to guide critical appraisal. For individual studies questions 1-3 and 6 are assessed and help determine the internal and external validity grades.
When synthesizing the evidence across studies, all questions are utilized to determine the grade for the level of evidence to answer the key question. The level of evidence may also be referred to as certainty or strength of evidence. 
Assessment of Bias Across Studies
One of the most common concerns for bias when determining conclusions from the synthesis of multiple studies is the risk of publication bias. In an attempt to find information on unpublished studies I searched clinicaltrials.gov. I also searched PubMed, EMBASE, and Web of Science using the search terms detailed above with limits activated to find conference proceedings and meeting abstracts in order to identify studies presented in these settings that may [19] not have been published in a journal due to the lack of significant findings. I also conducted a brief expert interview with a local expert in an attempt to identify if they knew of any studies performed without any data being published.
[20]
RESULTS
Search Results
I searched the databases on February 28, 2012 using the strategy described above and found the following number of records in each database: PUBMED-121, Cochrane-103, and EMBASE-105. I then removed any duplicate records and studies on non-human subjects to obtain 230 articles for title and abstract review. The second reviewer and I analyzed the title and abstracts for these studies and at this point we excluded studies based on study design, study population, or lack of outcomes or intervention related to this review's question. This resulted in 32 studies that went on for full text review. From these studies, I was unable to identify any additional studies from hand searches of their citations. After full text review, we excluded 23 studies based on the inclusion and exclusion criteria detailed in the methods section and 9
remained to be included in the review for a full critique and assessment. Figure 1 below shows this progression as a flow chart. It should be noted here that only studies assessing either vitamin C alone or a combination of vitamin C and E were identified and included in the rest of this review.
[21] Table 2 below gives information on each individual study included in the quality assessment. In summary, the studies included 18,262 women when the intervention was vitamin C and E with 9,151 in their control groups and 9,111 women in the intervention groups. For studies where the intervention was vitamin C only the studies included 226 women with 117 in the control groups and 109 in the intervention groups. Appendix B includes more information on the study characteristics, as well as some of the key points used to determine study quality. ** Study included a high and low risk group; however, many of the risk factors mentioned above were excluded from both groups and the high risk group was less than 30% of the study population
Study Characteristics
Quality of Studies
Using the quality criteria laid out in the methods section, we rated each study as good, fair, or poor. The grading of the studies is summarized in Table 3 and described here with additional information in Appendix B. Two studies, one by Haji Foghaha et al (28) and the second by Beazley et al (35) could not be appropriately assessed due to a lack of information available in their respective articles. Emails were sent to the contact information provided within the articles to request further information; however, no responses were received prior to the completion of this review. In the remaining seven studies, we rated three studies as good quality in respect to their internal validity and four graded as fair quality using the grading criteria given [23] in the methods section. The most common reasons we considered a study fair instead of good was either not enough information provided on the presence of risk factors and any differences between the intervention and control group or different rates of known risk factors when comparing the intervention and control group. When assessing the external validity, five studies were graded as good while two received grades of fair. One study received a fair grade due to differences between the study population and the US population based on demographic and risk factor characteristics. The other study received a fair grade due to its very limited study population, patients with type 1 diabetes limiting its generalizability. For studies dealing with a high risk population the external validity was graded based on its generalizability to high risk populations in the US and likewise for low risk studies, they were assessed with low risk US populations in mind. [24] et al (36) Not included in results of this review
Study Results
The individual risk ratios for each study are given in Table 4 below. When available, this data was directly abstracted from the study; however, if necessary the risk ratio and relevant confidence interval were calculated using methods described by Armitage and Berry. (37) For studies where the intervention included vitamin C and E the risk ratios ranged from 0.83 to 1.209. The study by McCance et al (33) reported a statistically significant risk ratio of 0.82 using a high risk population. Specifically, the population used for their study was women with preexisting Type 1 diabetes. However, it should be mentioned here that the rates for history of preeclampsia, hypertension, use of antihypertensive medications, and microalbuminuria were higher in the placebo group than the intervention group. Equalizing these risk factors for preterm birth, between the two groups would tend to push the risk ratio towards null. This will be discussed further in the section on synthesizing the results of all studies below. No other studies using vitamin C and E as the intervention reported statistically significant risk ratios.
Only one study where the intervention was vitamin C only was included in the results of this review and it reported a risk ratio of 0.548 which was not statistically significant. The study by Casanueva et al (29) used a low risk population in their study. 
Not included in results of this review
Synthesis of Study Results
The next step in this review was to use the information from above describing a studies characteristics, quality, and outcomes and synthesize some overall conclusions. Here I will discuss how this information was combined and point out key decisions made during the process and an analysis of the use of these results in public health and the clinical setting will follow below in the discussion section. As noted in the methods section above, the evidence level for the key question will be assessed for each intervention category and risk level using the USPSTF procedure manual as a guide. Therefore, I will report grades for the level of evidence as convincing, adequate, or inadequate.(27)
Vitamin C -Low Risk
Only one study was found using vitamin C only that was able to be assessed for quality and included in this review. The study by Casanueva et al(38) studied a low risk population which excluded women with medical disease, multiple gestations, and obstetrical indications for [26] a Cesarean section. In this study there was no statistically significant difference in preterm birth rates between the intervention (vitamin C 100mg/d) and the placebo group. The study included only 109 women and reported a minimal number of incidence rates for preterm birth risk factors resulting in fair internal validity. The study had fair external validity partly due to possible differences in natural vitamin intake levels and other risk factors between its source population in
Mexico and the general US population. The primary outcome of the study was premature rupture of membranes which is a likely reason the authors' did not report the incidence rate of previous preterm birth (and other risk factors) in the study population. Since this is the only study with vitamin C only as the intervention in a low risk group, I have graded the level of evidence to be inadequate to conclude whether vitamin C use in a low risk population will prevent preterm birth.(29)
Vitamin C -High Risk
No study was identified using Vitamin C only in a high risk population. Therefore, the evidence level for vitamin C use to prevent preterm labor in high risk women is considered inadequate.
Vitamin C and E -Low Risk
Three studies included in this review used vitamin C and E in low risk women. Two studies by Roberts et al (31) Roberts et al's study population was approximately twice the size as the other two studies combined. Given this data, the conclusion of this review is the level of evidence for vitamin C and E use during pregnancy is convincing that there is no effect on preterm birth rates in a low risk population.(30-32)
Vitmain C and E -High Risk
The remaining three studies in this review assessed the use of vitamin C and E in high risk study populations. Although there are more studies in this category, the total number of study participants is less than in the low risk studies: 3,780 high risk study participants versus 14,382 low risk study participants. Also, these studies had a higher degree of variability in their study population characteristics and internal and external validity. Only one study by Poston et al (34) was assessed to have good internal and external validity and also had the highest number of study participants with almost as many as the remaining studies combined. This study with 2,748 women possessing at least one obstetrical risk factor, including 21% having more than one risk factor, reported a non-statistically significant difference between the intervention group and placebo group that was slightly above null (RR=1.07).
[28]
The remaining two studies were deemed to contribute less to the level of evidence for the following reasons: The McCance et al(33) study with 749 women was rated fair partly due to its high risk of confounding (higher incidence of prior preeclampsia, hypertension, antihypertensive treatment, and microalbuminuria in the placebo group) that would push it's reported risk ratio of 0.83 closer to the null. The study had fair external validity mainly due to its low level of generalizability because it used only women with type 1 diabetes. Finally, Chappell et al's (36) study with 203 women had fair internal validity for a variety of reasons (adherence rates not reported, high dropout rate compared to other studies (~20%), and a higher proportion of women of African descent in the placebo group) and good external validity. Chappell et al reported a risk ratio of 1.209; however, the confidence interval was very wide due to the low sample size (95% CI=0.377-3.869). (33, 36, 39) Statistically combining the results of the three studies assessing vitamin C and E in high risk women would be a useful tool to help assess the level of evidence; however, it is beyond the scope of this review. Therefore, looking at the three studies and what they say about the evidence as an aggregate we considered the following key points: the number of study participants giving outcomes below the null (749) and above (3031) were not insignificant nor extremely large, all risk ratios approached null especially when accounting for possible confounders that would push the risk ratio closer to null in studies (33, 39) with results further from it, and the study with the best internal validity(34, 40) produced the results closest to null.
Based on this information we determined that the level of evidence is adequate that using vitamin C and E in high risk pregnant women will not decrease preterm birth rates. (33, 34, 36, 39, 40) [29] However, it may report data on the number of pre-term births as well and this data could be added to the body of evidence. Targeted searches of PubMed and EMBASE using the principal investigators name and dates of the study did not provide any further information on the study's results. However, since this study was not yet completed, its lack of article results in the database searches does not indicate publication bias.
Based on this information I did not find evidence for a publication bias; however, this is not evidence of a lack of publication bias either. On the other hand, most of the studies included in this review had an outcome consistent with a null risk factor and the primary concern with publication bias is a lack of these studies being reported. Therefore the risk of publication bias affecting this review is minimal.
[30]
DISCUSSION
Summary of Evidence
The original focus of this review was to determine the evidence available regarding vitamin C supplementation during pregnancy and its effect of the incidence of preterm birth.
Due to the variety in study populations present in the studies identified during the database searches we decided to divide our conclusions into four groups. The type of intervention the study used (vitamin C alone or C and E combined) and the study population risk profile (high or low) determined which group a study belonged in. Here we will discuss how the level of evidence available within each group can be used to direct health care.
Vitamin C -Low Risk
There was only one study identified that studied a low risk population with vitamin C alone as the intervention done by Casanueva et al. (38) The study produced a risk ratio with a wide confidence interval including the possibility of no effect; therefore the level of evidence for vitamin C in low risk women was considered inadequate. From a public health perspective, this level of evidence cannot be used to drive policy on the population level. Likewise given this level of evidence, this review cannot make any recommendations to be utilized by the clinician during individual patient encounters. The vitamin C dose was lower for this study than many of the other at 100mg/day. With this dose, no harms were identified during the study. However, detection of harms was not the target of the study and typically requires a larger study population than what the study obtained with 109 women participating. Therefore, while this study does not provide evidence for the use a vitamin C during pregnancy for prevention of preterm birth, it also [31] does not provide evidence against the continued use of multivitamin supplements containing vitamin C.
Vitamin C -High Risk
No study was identified with vitamin C alone as the intervention in a high risk population. Therefore, we are unable to make any recommendations on a population level to assist public health professionals or to aid in clinical decision making.
Vitamin C and E -Low Risk
The group of three studies using vitamin C and E in a low risk population were all well done and taken together produce convincing evidence that there is no effect of the rate of preterm birth with vitamin C 1000mg/day and vitamin E 400IU/day. For public health policy, this evidence argues against implementing this intervention in any widespread fashion. I would point out here that the evidence does not suggest the current recommendations for multivitamin use during pregnancy should be changed. These studies investigated a relatively high dose of vitamin C and E supplementation targeting the prevention of specific outcomes whereas multivitamin supplementation is an effective means to maintain adequate intake on a population level where the dietary intake varies greatly within the general population. For individual patients, the evidence is enough evidence showing a lack of benefit that a clinician should only recommend this treatment if the patient has a known deficiency of vitamin C or E or some other indication for the intervention. The studies did not provide any evidence of increased harms from the intervention with relatively high total number of study participants.
[32]
Vitamin C and E -High Risk
There were three studies using high risk populations with vitamin C and E as the intervention. From these studies I concluded the level of evidence was adequate to say vitamin C and E use during pregnancy for high risk groups would not reduce the rate of preterm birth.
Analogous to above for low risk groups, the evidence indicates there should not be a population wide recommendation to use vitamin C and E for prevention of preterm birth in high risk women. Also, as above, the evidence does not support the widespread use of vitamin C and E in the clinical setting to prevent preterm birth. However, if there is reason for a clinician to believe their patient has a specific need for vitamin C and E supplementation for other reasons, it may be useful for reasons other than prevention of preterm birth. Therefore, clinicians can make a judgment based on the patient if there is a perceived benefit other than what is covered by these studies.
Harms
None of the studies included in this review reported outcomes related to the typical side effects of vitamin C toxicity: diarrhea or other gastrointestinal disturbances. Xu et al (30) reported an increase risk of fetal loss or perinatal death and preterm premature rupture of membranes in their intervention group. Roberts et al(31),Rumbold et al (32) , and Poston et al (34) found an increased risk of gestational hypertension and the need for antihypertensive therapy within their intervention groups. Poston et al also found higher rates of small and growth restricted singleton babies born to women with diabetes taking vitamin C and E in some of their sub-group analyses. These harms provide more evidence against the widespread use of vitamin C to prevent preterm birth, especially without evidence of benefit.
[33]
Limitations of the Available Studies
One limitation of this review due to the studies included is because most studies had a primary outcome different than this review's outcome of interest which is preterm birth. When performing a trial, investigators invariably dedicate more effort to enhancing the study with respect to their primary outcome. The study is designed to provide the best data to analyze the link between the intervention and primary outcome by implementing better control for confounders, maintaining valid measurements, obtaining adequate sample sizes, etc. This also becomes a limitation in terms of the information provided in the article available to reviewers.
We could not assess the comparability between the intervention and placebo groups on some risk factors because they were not reported in the articles available. Risk factors that would not affect the primary outcome are typically not reported even though they may have a large effect on our review's outcome. Most studies included adequate randomization techniques which would limit any differences between the intervention and placebo group. We can assume the randomization would produce comparable groups. Therefore the limitation is the need for an assumption rather and not necessarily that the groups were not comparable.
One other limitation common in many of the studies included in this review was lack of any data obtained or at least not reported in the article on the background vitamin C intake of the study participants. Some of the studies used food surveys and other methods to derive some information on the level of vitamin C consumption in their participants. These methods have their own associated inaccuracies but they provided more data than the studies that did not report any information on this subject. Without this information we cannot make conclusions on whether there is a threshold intake level that would demonstrate some benefit in patients with poor nutritional statuses. Some of the studies focused on populations where poor nutrition was [34] more relevant; however, since we do not know how the intake levels in their populations compare to those in the studies in populations with better nutrition. Similarly although most studies had exclusion criteria related to intake of vitamin supplements containing vitamin C, the level of intake used varied among the studies and as above it would be difficult to know what amount of vitamin C intake would be confounding. Therefore, this can also be seen as a limitation of the available studies used in this review. The specific exclusion criteria are listed in Appendix B.
No study was identified in our search that used vitamin C alone in a high risk population.
Without any evidence for this population we were unable to make conclusions regarding the benefit or harm of the intervention.
Vitamin C toxicity is typically associated with diarrhea and other gastrointestinal disturbances when high doses >3grams per day are ingested. None of the studies used doses at this level or had populations large enough to have sufficient power to further investigate this harm. However, some negative differences between intervention and control groups were identified by the studies as mentioned above.
Another limitation of this review is related to the difference in preterm delivery due to spontaneous labor versus medically indicated iatrogenic causes of preterm birth. As mentioned in the introduction around 20% of all preterm births are secondary to other obstetrical complications. Most of the articles used in this review did not report data on the preterm birth rate separately for spontaneous labor versus other causes. Therefore, within the scope of this review I cannot draw any conclusions on the vitamin C's effect on the different causes of preterm birth.
[35]
Limitations of Our Review
One of the primary concerns of any systematic review is publication bias affecting the conclusions. Typically, publication bias would tend to push any outcome measure away from null and artificially enhance the benefits of the intervention. In general, it is impossible to prove that a bias is not present. I attempted as part of the review to look for evidence of publication bias to help determine the probability it is affecting our conclusions. I searched clinicaltrials.gov to look for registered studies that were completed but without available results. I talked to an expert in the field to found out if they could identify trials not included in the studies identified by my database search. I also searched multiple databases for conference abstracts and similar pieces of information about studies done that may not have been published as journal articles captured by my search. After performing all of the above, I did not find any trials that fit this review which would support a low probability of publication bias affecting my results.
However, I cannot eliminate the possibility completely and this should always be taken into account as a limitation of the review.
Another limitation of this review was the requirement that any individual study have information published in English to allow for the reviewers to assess the study and abstract the relevant data necessary for the review. This limitation is mitigated somewhat since most trials with study populations similar to the general US population are often published in English as well as any native languages. However, they are many trials that are not published in English.
This limitation can combine with publication bias by limiting the data of important trials performed in other languages that are not deemed 'important' enough to be translated for publication in English.
[36]
A limitation of every review is the possibility of missing trials published and present in the databases searched but missed by the reviewers due to a poor search strategy. A research librarian was consulted in developing the overall search strategy for this review. However, due to resource constraints the search needed to be focused some which may have excluded studies that would have contributed to this review. In particular, MEDLINE categories were utilized in the primary PUBMED search and filters were also used in the EMBASE search. Using these filters and MEDLINE indexing can exclude trials that may provide more evidence for this review. I did perform the search to find PUBMED results which were not yet indexed with MEDLINE to control for part of this limitation.
We excluded two studies identified from the database searches from the results of this review due to the lack of information present in the published article to properly assess the trials' validity. I attempted to obtain more information from the authors of each of these studies but did not receive anything before the conclusion of this review. The results of these two studies as reported in the articles we obtained were similar to those in the studies that were included in this review. Therefore, the conclusions drawn would not have changed dramatically. These two studies are examples of a limitation of reviews since they are only based on the information on each study that is provided to them by the authors. Additional information on any given trial may have affected the assessment of its internal or external validity as well as its inclusion in the review. Contacting the authors of the two identified studies was an attempt to mitigate this limitation but it is still present for these articles as well as all the articles included in the review.
[37]
CONCLUSIONS
Using vitamin C alone to prevent preterm birth was only addressed in one study identified by this review. The study had fair validity. Therefore, the level of evidence is inadequate to make any recommendations related to public health policy or clinical decision making. There were six studies on vitamin C and E which produce a high level of evidence showing no beneficial effect of the intervention on preterm birth rates. In addition, there was some evidence in the studies of increased harms in the intervention groups which means the harms may outweigh any unproven benefits related to preterm birth.
Typically the lack of studies on vitamin C alone combined with the biochemical evidence suggesting a benefit would encourage further research in this area. However, the biochemical evidence is based on the antioxidant properties of vitamin C. Therefore, studies using vitamin C and E, both antioxidants should also have showed a benefit based on the biochemical data.
However, eight studies on vitamin C and E in this review provided a high level of evidence of no benefit. If an effect had been seen with vitamin C and E, but not observed in the two vitamin C only studies, they would be a stronger impetus to perform more vitamin C only studies. This would help determine if the effect was due to vitamin C but not observed in the small studies performed thus far for some reason or due to vitamin E. However, since there did not appear to be an improvement even when using two antioxidants, there is less of an impetus to differentiate the effects of vitamin C and E based on the biochemical evidence alone.
[38]
APPENDIX A -SEARCH STRATEGY
The following searches were performed: 
APPENDIX B -QUALITY ASSESSMENT AND STUDY POPULATION SUMMARY
The tables below summarize some of the pertinent points found when assessing the quality of each study. The groups mentioned in the tables are the intervention and placebo group. Only information pertinent to the outcome of interest for this review is discussed below.
Also some details are not written below if they are not informative to the assessment process.
For instance, having similar age ranges in the groups or average parity are not reported as risk factors consistent between the groups but would be pointed out if they are inconsistent. Another example is that all studies provided results for the outcome of preterm birth that could be considered intention to treat and this review did not use any adjusted rates; therefore, a discussion of the analytical methods of the studies is not included. 
